Core Viewpoint - Hutchison China MediTech Limited (HCM) announced the latest and updated data from several studies of its self-developed compounds, which will be presented at the European Society for Medical Oncology (ESMO) Asia Congress in Singapore and the American Society of Hematology (ASH) Annual Meeting in Orlando in December 2025 [1] Group 1: Clinical Trials and Presentations - The first human clinical trial results of the anti-CD47 monoclonal antibody HMPL-A83 for the treatment of advanced solid tumors will be presented at the 2025 ESMO Asia Congress [1] - Results from the FRUSICA-2 registration study's Phase II portion, which examines fruquintinib in combination with sintilimab for second-line treatment of locally advanced or metastatic renal cell carcinoma, will also be disclosed at the 2025 ESMO Asia Congress [1] - The Phase II portion results of a study combining surufatinib with camrelizumab and chemotherapy for first-line treatment of metastatic pancreatic cancer will be presented at the same congress [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不 對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 HUTCHMED (China) Limited 和黃醫藥（中國）有限公司 （於開曼群島註冊成立的有限公司） （股份代號：13） 自願性公告 和黃醫藥將於2025年歐洲腫瘤內科學會 (ESMO) 亞洲年會和 2025年美國血液學會 (ASH) 年會公佈臨床數據 和黃醫藥（中國）有限公司（簡稱「和黃醫藥」或 「HUTCHMED」）今日宣佈和黃醫藥自主研發的化合物的數項研 究的最新及更新後的數據將於2025年12月5日至7日在新加坡召開的歐洲腫瘤內科學會（ESMO）亞洲年會，以及 2025年12月6日至9日在美國奧蘭多召開的美國血液學會（ASH）年會上公佈。 | 摘要標題 | 報告人/ 主要作者 報告詳情 | | | --- | --- | --- | | 奧希替尼聯合賽沃替尼用於治療EGFR突變伴MET過表達和/或奧希替尼治療後進展 | Se-Hoon Lee | 982P | | 的晚期非小細胞肺癌: S ...

Core Insights - The ITP drug treatment market in China is projected to grow, reaching 2.4 billion yuan in 2024, an increase of 200 million yuan from 2023, and is expected to reach approximately 2.8 billion yuan in 2025 [1][3][4] - Eltrombopag, a novel oral small molecule TPO receptor agonist, has shown excellent efficacy in treating ITP, significantly expanding treatment options for patients [1][4][7] - The sales of Eltrombopag in hospitals reached 376 million yuan in 2023, with an estimated 430 million yuan for the entire year of 2024 [1][4] ITP Drug Treatment Industry Pathway - ITP, or Immune Thrombocytopenic Purpura, is primarily treated with corticosteroids as the first-line therapy, while second-line treatments include platelet-stimulating drugs [2][4] - The incidence of ITP in adults in China is estimated at 5 to 10 per 100,000, with a projected 130,400 patients in 2024 [2][3] ITP Drug Treatment Industry Development Status - The ITP drug treatment market has been expanding, with a notable increase in treatment options due to ongoing research into the disease's pathophysiology [4][6] - The market is characterized by a growing number of patients and an increasing demand for effective treatments [2][3] ITP Drug Treatment Industry Chain - The upstream of the ITP drug treatment industry includes active pharmaceutical ingredients (APIs), chemical raw materials, and related equipment, while the midstream focuses on drug manufacturing [4][6] ITP Drug Treatment Competitive Landscape - Major companies in the domestic ITP drug market include Jiangsu Aosaikang Pharmaceutical, Jiangsu Hengrui Medicine, and Shenyang Sanofi Pharmaceutical, among others [2][6] - Several companies have received approval for Eltrombopag, indicating a competitive environment for generic versions of the drug [6][7] ITP Drug Treatment Development Trends - The treatment of ITP is moving towards targeted and precision medicine, with new therapies showing potential in regulating key immune nodes [7] - Future research may explore the combination of Eltrombopag with existing therapies to enhance treatment outcomes and achieve long-term remission for patients [7]

Core Viewpoint - The Mandatory Provident Fund (MPF) has experienced a decline in investment returns of 1.29% since November, resulting in an estimated investment loss of approximately HKD 19.8 billion, with an average loss of HKD 4,140 per member [1] Group 1: Investment Performance - The year-to-date return is projected to be HKD 191.3 billion, translating to an average gain of HKD 39,895 per member [1] - November marks the first month of losses after six consecutive months of positive returns since 2017, primarily influenced by valuation concerns in AI stocks and a cooling expectation for a Federal Reserve rate cut in December [1] Group 2: Asset Management - The total asset size of the MPF is expected to reach HKD 1.521 trillion by the end of November, down from HKD 1.538 trillion in October, equating to an average account balance of HKD 317,300 per member, a decrease of HKD 3,515 from October [1] - Despite the anticipated significant losses in the MPF, monetary and bond assets have emerged as the best-performing categories, while the "other equity funds" category showed remarkable performance with a 5.95% increase, led by the Manulife MPF Health Care Fund, highlighting the diversification benefits of the healthcare sector [1]

Core Insights - Three innovative drugs have made significant progress, potentially stabilizing the Hang Seng Biotechnology Index and the Hang Seng Innovative Drug Index [1] Group 1: Drug Developments - Innovent Biologics announced that its drug IBI362 (Mastuzumab Injection) has achieved primary and all key secondary endpoints in a Phase III clinical trial for moderate to severe obesity in China, with plans to submit a new drug application for weight control [1] - Junshi Biosciences' PD-1 inhibitor, H drug (Surulitinib), has been officially included in the NMPA's list of breakthrough therapies for perioperative treatment of gastric cancer, marking it as the first drug recognized for this indication [2] - Peijia Medical's PB-119 has received approval from the NMPA for its new drug application, leveraging unique PEGylation technology to enhance efficacy while reducing immunogenicity and gastrointestinal side effects [3] Group 2: Industry Trends - The introduction of the innovative drug directory by commercial insurance is expected to address the accessibility and affordability of high-priced innovative drugs, with policies increasingly favoring the development of high-quality innovative drugs [3] - Chinese innovative pharmaceutical companies are increasingly focusing on internationalization, transitioning from imitation to innovation, supported by favorable policies and abundant clinical resources [2][3] - The ongoing drug review reforms are releasing dividends that are propelling the Chinese innovative drug industry into a new era of "innovation output" [2]

Group 1 - Three innovative drugs have made significant progress, potentially stabilizing the Hang Seng Biotechnology Index and the Hang Seng Innovative Drug Index [1] - Innovent Biologics announced that its drug IBI362 has achieved primary and all key secondary endpoints in a Phase III clinical trial for obesity, with plans to submit a new drug application for weight control [1] - The drug IBI362 is a dual receptor agonist for glucagon and GLP-1, and is the first of its kind approved globally for obesity and type 2 diabetes management [1] Group 2 - Junshi Biosciences' PD-1 inhibitor, H drug, has been officially included in the breakthrough therapy list by the NMPA for use in perioperative treatment of gastric cancer, marking a significant recognition of its clinical value [2] - This breakthrough designation is expected to accelerate the review and approval process for H drug, filling a gap in immune therapy for gastric cancer [2] - The approval of PB-119 by the NMPA highlights the competitive advantage of the drug based on solid clinical data and innovative PEGylation technology, which balances efficacy and reduces side effects [1][3] Group 3 - The introduction of the innovative drug directory by commercial insurance is expected to address the accessibility and affordability of high-priced innovative drugs [3] - The National Healthcare Security Administration is encouraging the high-quality development of innovative drugs, indicating a warming trend in payment policies for innovative drugs [3] - Domestic pharmaceutical companies are actively transitioning towards innovation, supported by ongoing reforms in drug approval processes [3] Group 4 - Relevant Hong Kong stocks in the innovative drug sector include Heng Rui Medicine, Kelun-Botai Biopharmaceutical, and others, indicating a growing interest in the market [4]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5][48]. Core Insights - The pharmaceutical sector has shown stronger performance compared to the overall market, with a 3.29% increase in the biopharmaceutical sector, while the total A-share market declined by 0.09% [1][36]. - The report highlights a significant divergence in performance among different segments of the medical device market, with consumables growing faster than equipment and IVD products [2][19]. - The report emphasizes the long-term growth potential of the Chinese medical device market despite short-term challenges related to pricing and policy [2][20]. Summary by Sections Market Performance - The biopharmaceutical sector outperformed the overall market, with notable increases in various sub-sectors: chemical pharmaceuticals up 4.51%, bioproducts up 2.65%, medical services up 1.81%, medical devices up 1.77%, and traditional Chinese medicine up 4.08% [1][36]. Key Companies and Predictions - Major companies such as Mindray Medical, WuXi AppTec, and Aier Eye Hospital are rated as "Outperform" with projected net profits for 2024 ranging from 1.4 billion to 116.7 billion CNY [4][48]. - Mindray Medical is highlighted for its strong R&D and sales capabilities, benefiting from domestic medical infrastructure and international expansion [48]. - WuXi AppTec is recognized for its comprehensive drug development services, poised to benefit from the rapid growth of the global drug development outsourcing market [48]. Investment Strategy - The report suggests focusing on undervalued stocks in the medical device and pharmacy sectors, which have already reflected risks from policies like centralized procurement [46][47]. - It recommends monitoring the clinical progress of innovative drugs overseas and emphasizes the importance of global clinical data for commercialization [47][48]. Recommended Stocks - The report lists several recommended stocks, including Mindray Medical, WuXi AppTec, Aier Eye Hospital, and others, indicating their strong market positions and growth potential [48][49].

Summary of the Conference Call for Hodgman Company Industry and Company Overview - The conference call pertains to Hodgman Company, a biopharmaceutical firm focused on oncology and autoimmune disease treatments, with a significant presence in both the Chinese and global markets [2][3][4]. Key Points and Arguments Product Pipeline and Performance - **Orpathys**: A carbonic anhydrase inhibitor for lung cancer, currently commercialized in China, with a Phase III clinical trial in collaboration with AstraZeneca expected to yield data in mid-2026, aiming for global approval by 2027 [2][3]. - **Cavatak**: A colorectal cancer treatment with sales of approximately $616 million in the first half of 2025, showcasing Hodgman's strength in the Chinese market and global competitiveness [3]. - **Tequila**: A top-selling oncology drug, recently approved for metastatic colorectal cancer, with expected growth driven by markets in Europe and Japan. It has received approval for endometrial cancer in China and is under investigation for second-line kidney cancer, anticipated to be approved by late 2026 [2][8]. - **SAFFRON Trial**: A Phase II clinical trial for a second-line EGFR mutation non-small cell lung cancer drug, with results expected in mid-2026. If successful, it could lead to U.S. approval around 2027, targeting patients with c-MET gene amplification [10][11]. Financial Guidance and Market Strategy - The company has adjusted its revenue guidance downward due to weak sales in the first half of 2025, attributed to increased competition and infrastructure restructuring for compliance, which has temporarily impacted sales activities [5][6]. - Despite short-term challenges, Hodgman anticipates improved performance in the second half of 2025, driven by recovery in the Chinese market [5][6]. ATTC Platform - The ATTC (Antibody-Targeted Therapy Conjugate) platform is a novel treatment modality that uses small molecule targeted drugs instead of chemical toxins, aiming to reduce toxicity and enhance selectivity. Currently in Phase I trials, it shows significant potential for future applications [4][6]. - Hodgman is actively seeking partnerships to advance the ATTC platform, with interest from multinational pharmaceutical companies [7]. Market Opportunities and Challenges - The Chinese market remains crucial for Hodgman, but competition is fierce, with lower prices and limited profit margins. The company is focusing on expanding its presence in higher-margin markets like the U.S., Europe, and Japan [5][6]. - The potential market size for the second-line EGFR mutation treatment in the U.S. and China is estimated at around $1 billion, with Hodgman aiming to capture significant market share through ongoing trials and approvals [11][12]. Other Important Insights - Hodgman has a strong balance sheet and stable revenue from its commercialized products, positioning it well for future growth [4][13]. - The company is optimistic about the ITP inhibitor project, which is expected to resubmit data in mid-2026 for potential approval in 2027, marking its entry into the autoimmune disease market [12]. This summary encapsulates the critical aspects of Hodgman Company's conference call, highlighting its product pipeline, financial outlook, strategic initiatives, and market positioning.

Core Viewpoint - The article emphasizes the growing collaboration between China and Saudi Arabia in capital markets, particularly in high-tech sectors, and highlights the potential for mutual investment opportunities [1][5]. Group 1: Capital Market Cooperation - The Saudi Stock Exchange (Tadawul) has signed memorandums of understanding with both the Shanghai and Shenzhen stock exchanges, as well as the Hong Kong Stock Exchange, to explore joint listings and fintech collaborations [2]. - The cooperation has progressed to the launch of cross-border ETF products and ongoing discussions about cross-listing and dual listing of companies [2][5]. - The market capitalization of the Saudi Stock Exchange has reached $2.6 trillion, with over $100 billion of investments coming from international investors [5]. Group 2: Investment Opportunities - The Saudi Stock Exchange is inviting Chinese investment institutions to participate in its capital market, leveraging the success of Saudi Arabia's Vision 2030 [5][6]. - There is a significant interest from top Chinese asset management companies in understanding the Saudi capital market and investment details [5]. - The introduction of Saudi Depositary Receipts (SDRs) has been approved, facilitating cross-listing opportunities for Chinese companies [6][7]. Group 3: Future Prospects - The article discusses the potential for further collaboration in the next three to five years, focusing on launching more ETF products and enhancing investment channels between the two countries [8]. - There is a strong emphasis on deepening cooperation in complementary industries, particularly in artificial intelligence (AI), where both countries see significant growth potential [8].

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector, indicating a positive outlook for investment opportunities in this industry [4]. Core Insights - The pharmaceutical sector is experiencing performance divergence, with the medical device segment showing signs of a turning point [1]. - For the first three quarters of 2025, the total revenue of 461 A-share pharmaceutical companies was CNY 17,876.4 billion, a year-on-year decrease of 2%, while net profit attributable to shareholders was CNY 1,435.7 billion, down 6.43% year-on-year [10][29]. - In Q3 2025, the industry showed signs of improvement, with total revenue reaching CNY 5,936.9 billion, a year-on-year increase of 0.51%, and net profit of CNY 419.4 billion, down only 0.95% year-on-year [33]. Summary by Sections 1. Market Review - The pharmaceutical and biotechnology index increased by 21.1% year-to-date, outperforming the CSI 300 index by 3.17 percentage points, with the medical services sub-sector showing the highest growth at 40.25% [17]. 2. Industry Performance - The medical commercial and medical service sectors are the only segments showing positive revenue growth in the first three quarters of 2025, with revenues of CNY 7,723.1 billion and CNY 1,374.9 billion, respectively [29]. - The chemical preparation and medical service sectors demonstrated significant profit growth in Q3, with net profits increasing by 10.43% and 25.80%, respectively [33]. 2.1 Raw Materials and Auxiliary Drugs - The raw materials sector reported total revenue of CNY 670.65 billion, down 7.56% year-on-year, with net profit of CNY 61.01 billion, down 11.18% year-on-year [35]. - The report suggests focusing on high-quality raw material companies such as Shanhe Pharmaceutical and Weier Pharmaceutical [42]. 2.2 Chemical Preparations & Innovative Drugs - The chemical preparations sector achieved total revenue of CNY 3,050.25 billion, down 3.79% year-on-year, with net profit of CNY 320.73 billion, down 15.09% year-on-year [43]. - The report highlights the significant growth of innovative drugs, with 43 new drugs approved in the first half of 2025, a 59% increase year-on-year [47]. 2.3 Traditional Chinese Medicine - The traditional Chinese medicine sector reported total revenue of CNY 2,512.22 billion, down 3.84% year-on-year, with net profit of CNY 292.63 billion, down 1.16% year-on-year [49]. - The sector is transitioning towards quality-oriented development, with a focus on improving the quality of raw materials [57]. 2.4 Biological Products - The biological products sector reported total revenue of CNY 802.59 billion, down 15.34% year-on-year, with net profit of CNY 123.48 billion, down 28.73% year-on-year [58]. - The report suggests monitoring companies with strong internationalization efforts, such as Kangtai Biological [62]. 2.5 Medical Commerce - The medical commerce sector achieved total revenue of CNY 7,723.15 billion, up 0.56% year-on-year, with net profit of CNY 160.9 billion, up 4.94% year-on-year [63]. - The report emphasizes the importance of diversified development in pharmacies, supported by national policies promoting health consumption [68].